Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

2023-508312-39-00 Protocol AB-101-001 Human pharmacology (Phase I) - First administration to humans Ended

Start 13 Dec 2024 · End 26 Nov 2025 · Status Ended · 3 EU/EEA countries · 5 sites · Protocol AB-101-001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 67
Countries 3
Sites 5

Chronic hepatitis B virus Infection

Key facts

Sponsor
Arbutus Biopharma Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Virus Diseases [C02]
Trial duration
13 Dec 2024 → 26 Nov 2025
Decision date (initial)
2024-12-09
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-508312-39-00
ClinicalTrials.gov
NCT05960240

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Chronic hepatitis B virus Infection

VersionLevelCodeTermSystem organ class
20.1 PT 10008910 Chronic hepatitis B 100000004862

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Arbutus Biopharma Inc.

Sponsor organisation
Arbutus Biopharma Inc.
Address
701 Veterans Circle
City
Warminster
Postcode
18974-3531
Country
United States

Scientific contact point

Organisation
Arbutus Biopharma Inc.
Contact name
Tilly Varughese

Public contact point

Organisation
Arbutus Biopharma Inc.
Contact name
Varun Sharma

Locations

3 EU/EEA countries · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Bulgaria Ended 10 2
Italy Ended 7 2
Romania Ended 10 1
Rest of world
Hong Kong, Ukraine, New Zealand, Moldova, Republic of, Singapore
40

Investigational sites

Bulgaria

2 sites · Ended
Umbal - Prof. D-R Stoyan Kirkovich AD
Department of Gastroenterology, Ulitsa General Stoletov 2, 6003, Stara Zagora
Military Medical Academy
Clinic of Gastroenterology, Ulitsa Sveti Georgi Sofiyski 3, 1606, Sofiya

Italy

2 sites · Ended
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
Gastroenterology and Hepatology Unit, Via Francesco Sforza 35, 20122, Milan
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Department of Medicine, SC Gastroenterology 1, Hepatology and Transplant, Piazza Oms 1, 24127, Bergamo

Romania

1 site · Ended
Institutul National De Boli Infectioase Prof.Dr.Matei Bals
Infectious Diseases dept., Strada Dr. Calistrat Grozovici Nr. 1, 021105, Bucharest

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Bulgaria 2024-12-17 2025-09-12 2025-01-21 2025-05-13
Italy 2025-02-21 2025-11-25 2025-03-04 2025-05-13
Romania 2024-12-13 2025-11-18 2024-12-18 2025-05-13

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-07 Italy Acceptable
2024-12-02
2024-12-04
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-01-16 Italy Acceptable
2024-12-02
2025-01-16
3 SUBSTANTIAL MODIFICATION SM-2 2025-02-12 Italy Acceptable 2025-03-18
4 SUBSTANTIAL MODIFICATION SM-1 2025-02-13 Acceptable 2025-03-24
5 SUBSTANTIAL MODIFICATION SM-3 2025-02-13 Acceptable 2025-04-02
6 NON SUBSTANTIAL MODIFICATION NSM-2 2025-08-20 Italy Acceptable 2025-08-20
7 NON SUBSTANTIAL MODIFICATION NSM-3 2025-08-27 Italy Acceptable 2025-08-27